581 related articles for article (PubMed ID: 3097872)
21. Influence of exogenous and endogenous tissue-type plasminogen activator on the lysability of clots in a plasma milieu in vitro.
Zamarron C; Lijnen HR; Collen D
Thromb Res; 1984 Aug; 35(3):335-45. PubMed ID: 6431630
[TBL] [Abstract][Full Text] [Related]
22. In vitro simulation of therapeutic thrombolysis with microtiter plate clot-lysis assay.
Stief TW
Clin Appl Thromb Hemost; 2006 Jan; 12(1):21-32. PubMed ID: 16444431
[TBL] [Abstract][Full Text] [Related]
23. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--I. Fibrinolytic and fibrinogenolytic properties in human plasma in vitro of urokinases obtained from human urine or by recombinant DNA technology.
Zamarron C; Lijnen HR; Van Hoef B; Collen D
Thromb Haemost; 1984 Aug; 52(1):19-23. PubMed ID: 6495259
[TBL] [Abstract][Full Text] [Related]
24. Effect of standard heparin and a low molecular weight heparin on thrombolytic and fibrinolytic activity of single-chain urokinase plasminogen activator in vitro.
Lourenço DM; Dosne AM; Kher A; Samama M
Thromb Haemost; 1989 Nov; 62(3):923-6. PubMed ID: 2556812
[TBL] [Abstract][Full Text] [Related]
25. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
[TBL] [Abstract][Full Text] [Related]
26. Mechanisms of plasminogen activation by mammalian plasminogen activators.
Lijnen HR; Collen D
Enzyme; 1988; 40(2-3):90-6. PubMed ID: 3139404
[TBL] [Abstract][Full Text] [Related]
27. The kinetics of plasminogen activation by thrombin-cleaved pro-urokinase and promotion of its activity by fibrin fragment E-2 and by tissue plasminogen activator.
Liu JN; Gurewich V
Blood; 1993 Feb; 81(4):980-7. PubMed ID: 8428004
[TBL] [Abstract][Full Text] [Related]
28. Characterization of a fusion protein consisting of amino acids 1 to 263 of tissue-type plasminogen activator and amino acids 144 to 411 of urokinase-type plasminogen activator.
Nelles L; Lijnen HR; Collen D; Holmes WE
J Biol Chem; 1987 Aug; 262(22):10855-62. PubMed ID: 2956260
[TBL] [Abstract][Full Text] [Related]
29. Comparison of intrathecally administered urokinase, tissue-type plasminogen activator, and combination of urokinase and lysine-plasminogen for clot lysis after experimental subarachnoid hemorrhage in dogs.
Kajimoto Y; Ohta T; Kuroiwa T
Neurosurgery; 1997 Mar; 40(3):572-7. PubMed ID: 9055298
[TBL] [Abstract][Full Text] [Related]
30. Effects of pro-urokinase and urokinase on the fibrinolytic system in man.
Trübestein G; Popov S; Wolf H; Welzel D
Haemostasis; 1987; 17(4):238-44. PubMed ID: 2442078
[TBL] [Abstract][Full Text] [Related]
31. Specific fibrinolytic properties of different molecular forms of pro-urokinase from a monkey kidney cell culture.
Rijken DC; Binnema DJ; Los P
Thromb Res; 1986 Jun; 42(6):761-8. PubMed ID: 2425448
[TBL] [Abstract][Full Text] [Related]
32. Differences between neonates and adults in the urokinase-plasminogen activator (u-PA) pathway of the fibrinolytic system.
Ries M; Zenker M; Gaffney PJ
Thromb Res; 2000 Nov; 100(4):341-51. PubMed ID: 11113278
[TBL] [Abstract][Full Text] [Related]
33. Differences in the activation rates of plasminogen by tissue plasminogen activator and urokinase.
Takada A; Shizume K; Cho M; Takada Y
Thromb Res; 1987 Feb; 45(4):371-81. PubMed ID: 2437668
[TBL] [Abstract][Full Text] [Related]
34. Fibrin-specific and effective clot lysis requires both plasminogen activators and for them to be in a sequential rather than simultaneous combination.
Pannell R; Li S; Gurewich V
J Thromb Thrombolysis; 2017 Aug; 44(2):210-215. PubMed ID: 28600623
[TBL] [Abstract][Full Text] [Related]
35. Characterization of a recombinant chimeric plasminogen activator with enhanced fibrin binding.
Jiao J; Yu M; Ru B
Biochim Biophys Acta; 2001 Apr; 1546(2):399-405. PubMed ID: 11295444
[TBL] [Abstract][Full Text] [Related]
36. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
Guimarães AH; Rijken DC
Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
[TBL] [Abstract][Full Text] [Related]
37. Effects of fibrin on the enhanced activation of plasminogen by urokinase and tissue plasminogen activator: role of cross-link.
Takada A; Watahiki Y; Takada Y
Thromb Res; 1986 Mar; 41(5):605-13. PubMed ID: 3083529
[TBL] [Abstract][Full Text] [Related]
38. The level of extrinsic plasminogen activator (t-PA) during clotting as a determinant of the rate of fibrinolysis; inefficiency of activators added afterwards.
Brommer EJ
Thromb Res; 1984 Apr; 34(2):109-15. PubMed ID: 6539513
[TBL] [Abstract][Full Text] [Related]
39. Whole blood clot lysis in newborns and adults after adding different concentrations of recombinant tissue plasminogen activator (Rt-PA).
Trusen B; Ries M; Zenker M; Rauh M; Beinder E; Keuper H; Harms D
Semin Thromb Hemost; 1998; 24(6):599-604. PubMed ID: 10066156
[TBL] [Abstract][Full Text] [Related]
40. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
